Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Review

Clinical Trial

Randomized Controlled Trial

Research Support, N.I.H., Extramural

Comparative Study

Research Support, N.I.H., Intramural

Research Support, American Recovery and Reinvestment Act

Multicenter Study

Publication Year

From

Quick links

Individual year

2020

2014

2013

2012

2010

2009

2007

2006

2004

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Tolcapone""[mesh_terms]

11 Results

Searching titles within these results

Issues important for rational COMT inhibition.

J Dingemanse

Neurology 2001;55(11 Suppl 4):S24-7; discussion S28-32

Full Text

Abstract

3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing -Synuclein.

Risa Isonaka, Yunden Jinsmaa, Yehonatan Sharabi, David S Goldstein

The Journal of pharmacology and experimental therapeutics 2020;372(2):157-165

Free Full Text

Abstract

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Nuno Borges

Drug safety 2004;26(11):743-7

Full Text

Abstract

Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Wilfried Kuhn, Thomas Müller

European journal of clinical pharmacology 2007;62(6):447-50

Full Text

Abstract

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

Nuno Borges

Expert opinion on drug safety 2006;4(1):69-73

Full Text

Abstract

COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition.

Sarah M Farrell, Elizabeth M Tunbridge, Sven Braeutigam, Paul J Harrison

Biological psychiatry 2012;71(6):538-44

Free Full Text

Abstract

Telescoping phenomenon in pathological gambling: association with gender and comorbidities.

Jon E Grant, Marc E Mooney, Brian L Odlaug

The Journal of nervous and mental disease 2013;200(11):996-8

Free Full Text

Abstract

Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.

Lei Z Robinson, Natalia Reixach

Biochemistry 2014;53(41):6496-510

Free Full Text

Abstract

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Urszula Adamiak, Maria Kaldonska, Gabriela Klodowska-Duda, Elzbieta Wyska, Krzysztof Safranow, Monika Bialecka, Barbara Gawronska-Szklarz

Clinical neuropharmacology 2010;33(3):135-41

Full Text

Abstract

Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.

Panos Bitsios, Panos Roussos, Stella G Giakoumaki

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;33(13):3058-68

Free Full Text

Abstract

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.

Vincent Ries, Roland Selzer, Tobias Eichhorn, Wolfgang H Oertel, Karla Eggert

Clinical neuropharmacology 2010;33(3):142-50

Full Text

Abstract

Results: 1 – 11 / 11

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Tolcapone""[mesh_terms]

Issues important for rational COMT inhibition.

3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing -Synuclein.

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition.

Telescoping phenomenon in pathological gambling: association with gender and comorbidities.

Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.

Results for
""Tolcapone""[mesh_terms]